Ketamine Therapy

At-home ketamine therapy combines remote psychiatric evaluation with self-administered ketamine (typically sublingual tablets or nasal spray) for treating depression and anxiety. The concept exploded in 2021 when the DEA temporarily waived the Ryan Haight Act’s in-person requirement during COVID-19, enabling telehealth companies like Mindbloom and Better U to offer virtual assessments with medication delivered to patients’ homes.

Research on over 11,000 patients shows this approach can be both safe and effective, with response rates comparable to in-clinic treatment while dramatically reducing barriers to access, eliminating travel requirements, lowering costs, and allowing patients to experience therapy in the comfort of their own environment with remote monitoring and integration support that mimics traditional psychedelic-assisted therapy protocols.